

Dr. Andy Chevigné studied biochemistry at the University of Liège (Belgium) and obtained his PhD from the Centre for Protein Engineering (ULiège) and the Laboratory of Applied Genetics (Free University Brussels, ULB). He joined the Laboratory of Retrovirology of the Luxembourg Institute of Health (LIH) in 2008 to investigate the role of chemokine receptors in HIV-1 entry and became an independent group leader in 2011. He is currently heading the group of Immuno-Pharmacology and Interactomics at the Department of Infection and Immunity of LIH, which has as main research focus the study of chemokine receptor signalling, modulation and functions. He is also Associate Professor at the Faculty of Biomedical Sciences and Preclinical Studies at the University of Liège. He published over 60 peer-reviewed articles and book chapters. He is inventor on four patents and was co-awarded the Galien prize of Pharmacology 2019 for his research on atypical chemokine receptors. He is also member of the management committee of ERNEST and is part of ONCORNET2 network.